These drugs mimic a hormone found in the body and are approved by the FDA to treat diabetes and help manage weight
Underdosing running 10-20 mcg/day chronically is one of the more common reasons community users describe seeing nothing
The current focus extends beyond the incretin pathway to include poly-agonist therapies, activators of energy expenditure, and entirely new mechanistic classes
The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: modulation of BDNF/CREB, Nrf2 and lipocalin 2
Orforglipron (Foundayo): a daily pill from Eli Lilly The FDA approved orforglipron, branded Foundayo, for weight management in April 2026
Long term use of beinaglutide, a recombinant human GLP-1(7-36) acid, was demonstrated to reduce the body weight and improve steatosis (194)